Marcos de Lima, MD, of The Ohio State University, joins Chadi Nabhan, MD, MBA, FACP, at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss cellular therapy.
Dr. de Lima discusses progress and remaining challenges with allogeneic chimeric antigen receptor (CAR) T-cell therapy. He also highlights the obstacles he sees in commercializing allogeneic CAR-T, noting that “ironically,” one of the obstacles is the “success of the current product.”
Dr. Nabhan and Dr. de Lima also discuss autologous CAR-T products and the disparities in CAR-T access that have been observed in the United States and throughout the world.